Jun/iStock via Getty Images Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a clinical-stage biotechnology company focusing on developing treatments for immune-mediated inflammatory diseases. Its leading drug candidate is Reproxalap for dry eye and allergic conjunctivitis. It is a RASP modulator that reduces the generation of pro-inflammatory cytokines, a critical step for treating various ocular conditions. ALDX will resubmit in the first semester of 2024 the FDA approval request for this drug applied to d ...